Shuanglian Li

发表

Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function

P. Kwok, T. Ferrin, K. Giacomini, 2009, The Pharmacogenomics Journal.

Population pharmacokinetics of recombinant factor VIII Fc fusion protein

I. Nestorov, M. Rogge, T. Ludden, 2015, Clinical pharmacology in drug development.

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

M. Ozelo, C. Négrier, A. Shapiro, 2015, British journal of haematology.

Japanese subject subpopulation analysis of B-LONG: a Phase 3 study of long-acting recombinant factor IX Fc fusion protein

T. Matsushita, M. Taki, M. Shima, 2015 .

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B

I. Nestorov, J. Gobburu, T. Ludden, 2014, Clinical Pharmacokinetics.

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

L. Valentino, A. Shapiro, G. Pierce, 2013 .

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

hemophilia A Phase 3 study of recombinant factor VIII Fc fusion protein in severe

J. Dumont, I. Nestorov, D. Perry, 2014 .

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

G. Pierce, Haiyan Jiang, Shuanglian Li, 2013 .

Using DTA and DTAARRAY Variables and Programming in WinNonlin ASCII Models to Streamline User-Defined Calculation and Data Analysis

R. Bowsher, Shuanglian Li, A. Vick, 2015, The AAPS Journal.

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

John Kurhanewicz, Youcai Zhang, Kevan M. Shokat, 2014, Proceedings of the National Academy of Sciences.

Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice

Swati S. More, K. Giacomini, Shuzhong Zhang, 2010, Pharmaceutical Research.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

J. Neal, Gregory Riely, D. Costa, 2021, Cancer discovery.

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

J. Neal, Jianchang Lin, L. Horn, 2020 .

Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue

Swati S. More, K. Giacomini, S. Yee, 2010, Molecular Cancer Therapeutics.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

E. Burchard, K. Giacomini, S. Yee, 2009, Pharmacogenetics and genomics.

circACTR2: A Novel Mechanism Regulating High Glucose-Induced Fibrosis in Renal Tubular Cells via Pyroptosis.

Lulu Li, Qiuling Fan, Shuanglian Li, 2020, Biological & pharmaceutical bulletin.

Inter-laboratory evaluation of the bioluminescent Salmonella reverse mutation assay using 10 model chemicals.

Jiri Aubrecht, Shuanglian Li, Toshiaki Hayashi, 2009, Mutagenesis.

A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice

E. Blomme, Shuanglian Li, W. Duan, 2006, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

P. Jänne, J. Neal, Gregory Riely, 2019, Annals of Oncology.

P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials

P. Jänne, J. Neal, D. Costa, 2017 .

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

D. Perry, L. Valentino, M. Ozelo, 2013 .

CircPDE4B inhibits retinal pathological angiogenesis via promoting degradation of HIF-1α though targeting miR-181c.

Yan Deng, Shuanglian Li, Hongping Chen, 2020, IUBMB life.

Global research status and trends of bronchiectasis in children from 2003 to 2022: A 20-year bibliometric analysis

Xueer Wang, D. Tian, Tingting Gong, 2023, Frontiers in Pediatrics.

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

J. Neal, Gregory Riely, D. Costa, 2019, Journal of Clinical Oncology.

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.

S. Ou, Y. Ohe, E. Felip, 2023, Future oncology.

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

P. Jänne, J. Neal, Gregory Riely, 2018 .

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A

D. Perry, D. Quon, J. Mahlangu, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

J. Kurhanewicz, K. Shokat, K. Giacomini, 2014, Proceedings of the National Academy of Sciences.

Response to Gringeri et al.: ‘recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling’

A. Shapiro, Shuanglian Li, S. Li, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Population pharmacokinetics of recombinant factor VIII Fc fusion protein

S. Neelakantan, Shuanglian Li, Thomas M. Ludden, 2015, Clinical pharmacology in drug development.